Payment overview · 2025
General Payments
$146.16
7 reported records · 4 companies
Healthcare provider profile · identity verified
Kara Holdren
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CAMDEN ON GAULEY, WV · NPI 1033519558
Verified facts
What the public records show
CMS Open Payments records show Kara Holdren received $146.16 in general payments during 2025 across 7 reported records.
ABBVIE INC. accounted for 58.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $85.26 | 58.3% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $25.64 | 17.5% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $18.95 | 13.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.31 | 11.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $146.16 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $40.55 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.77 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.77 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $25.64 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 245 | 57 |
| Losartan Potassium | Losartan Potassium | 222 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 201 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 200 | 53 |
| Montelukast Sodium | Montelukast Sodium | 158 | 34 |
| Furosemide | Furosemide | 153 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 139 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 138 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 130 | 39 |
| Lisinopril | Lisinopril | 129 | 30 |
| Atorvastatin Calcium | Atorvastatin Calcium | 119 | 31 |
| Ezetimibe | Ezetimibe | 108 | 31 |
| Gabapentin | Gabapentin | 104 | 21 |
| Metformin Hcl Er | Metformin Hcl | 98 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 28 |
| Famotidine | Famotidine | 92 | 20 |
| Potassium Chloride | Potassium Chloride | 86 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 18 |
| Ozempic | Semaglutide | 78 | 14 |
| Metformin Hcl | Metformin Hcl | 77 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 12 |
| Fenofibrate | Fenofibrate | 68 | 15 |
| Simvastatin | Simvastatin | 68 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 14 |
| Eliquis | Apixaban | 59 | 14 |
| Meloxicam | Meloxicam | 59 | 16 |
| Buspirone Hcl | Buspirone Hcl | 57 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | 17 |
| Ibuprofen | Ibuprofen | 55 | 16 |
| Baclofen | Baclofen | 49 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 47 | 17 |
| Trazodone Hcl | Trazodone Hcl | 45 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 12 |
| Atenolol | Atenolol | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 42 | 11 |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 39 | 11 |
| Cefdinir | Cefdinir | 36 | 26 |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | suppressed |
| Fluconazole | Fluconazole | 33 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 33 | 13 |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | suppressed |
| Prednisone | Prednisone | 29 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Ibu | Ibuprofen | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Alprazolam | Alprazolam | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Carvedilol | Carvedilol | 20 | suppressed |
| Nystatin | Nystatin | 20 | 12 |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Klayesta | Nystatin | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $146.16 · 7 records | ABBVIE INC. | MAVYRET, MOUNJARO, QULIPTA, REXULTI, UBRELVY, VRAYLAR, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error